Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026
Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung cancer. SHANGHAI, Oct. 27, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
